ReviewThe European journal of health economics : HEPAC : health economics in prevention and care2024

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.

Daniel Tobias Michaeli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.